You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIsosorbide Mononitrate
Accession NumberDB01020  (APRD00528)
TypeSmall Molecule
GroupsApproved
DescriptionIsosorbide mononitrate is a drug used principally in the treatment of angina pectoris and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold by AstraZeneca under the trade name Imdur. Isosorbide mononitrate is used to for the the prophylactic treatment of angina pectoris; that is, it is taken in order to prevent or at least reduce the occurrence of angina. Research on Isosorbide mononitrate as a cervical ripener to reduce time at hospital to birth is supportive. Isosorbide mononitrate is an active metabolite of isosorbide dinitrate and exerts qualitatively similar effects. Isosorbide mononitrate reduces the workload of the heart by producing venous and arterial dilation. By reducing the end diastolic pressure and volume, isosorbide mononitrate lowers intramural pressure, hence leading to an improvement in the subendocardial blood flow. The net effect when administering isosorbide mononitrate is therefore a reduced workload for the heart and an improvement in the oxygen supply/demand balance of the myocardium. The adverse reactions which follow have been reported in studies with isosorbide mononitrate: Very common. Headache predominates (up to 30%) necessitating withdrawal of 2 to 3 % of patients, but the incidence reduces rapidly as treatment continues . Common. Tiredness, sleep disturbances (6%) and gastrointestinal disturbances (6%) have been reported during clinical trials with isosorbide mononitrate modified release tablets, but at a frequency no greater than for placebo. Hypotension (4 to 5%), poor appetite (2.5%), nausea (1%). Adverse effects associated with the clinical use of the drug are as expected with all nitrate preparations. They occur mainly in the early stages of treatment. Hypotension (4%) with symptoms such as dizziness and nausea (1%) have been reported. These symptoms generally disappear during long-term treatment. Other reactions that have been reported with isosorbide mononitrate modified release tablets include tachycardia, vomiting, diarrhoea, vertigo and heartburn
Structure
Thumb
Synonyms
IS 5-MN
IS-5-MN
IS-5MN
ISMN
Iso-5-mononitrate
Isosorbide 5-mononitrate
Isosorbide 5-nitrate
Isosorbide-5-mononitrate
isosorbidi mononitras
mononitrate d'isosorbide
mononitrato de isosorbida
Monosorbitrate
External Identifiers
  • AHR-4698
  • BM 22.145
  • BM-22.145
  • BM-22145
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Isosorbide MononitrateTablet10 mg/1OralPhysicians Total Care, Inc.2012-07-18Not applicableUs
Isosorbide MononitrateTablet10 mg/1OralKremers Urban Pharmaceuticals Inc.1993-06-30Not applicableUs
Isosorbide MononitrateTablet20 mg/1OralCarilion Materials Management1993-06-30Not applicableUs
Isosorbide MononitrateTablet20 mg/1OralKremers Urban Pharmaceuticals Inc.1993-06-30Not applicableUs
MonoketTablet20 mg/1OralKremers Urban Pharmaceuticals Inc.1993-06-30Not applicableUs
MonoketTablet10 mg/1OralKremers Urban Pharmaceuticals Inc.1993-06-30Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ImdurTablet, extended release120 mg/1OralSchering Corporation2006-01-05Not applicableUs
ImdurTablet, extended release30 mg/1OralSchering Corporation2006-01-05Not applicableUs
ImdurTablet, extended release60 mg/1OralSchering Corporation2006-01-05Not applicableUs
IsosorbideTablet, film coated, extended release30 mg/1OralREMEDYREPACK INC.2013-05-15Not applicableUs
IsosorbideTablet, film coated, extended release30 mg/1OralCardinal Health2006-03-302015-12-29Us
IsosorbideTablet, film coated, extended release30 mg/1OralCarilion Materials Management2006-03-30Not applicableUs
IsosorbideTablet, extended release30 mg/1OralREMEDYREPACK INC.2012-09-17Not applicableUs
IsosorbideTablet, film coated, extended release60 mg/1OralREMEDYREPACK INC.2013-05-29Not applicableUs
IsosorbideTablet, film coated, extended release60 mg/1OralCardinal Health2006-03-302015-12-29Us
IsosorbideTablet, film coated, extended release30 mg/1OralWest Ward Pharmaceuticals Corp2006-03-30Not applicableUs
IsosorbideTablet, film coated, extended release60 mg/1OralWest Ward Pharmaceuticals Corp2006-03-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralKremers Urban Pharmaceuticals Inc.1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralMc Kesson Contract Packaging2013-06-13Not applicableUs
Isosorbide MononitrateTablet30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-12-19Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralQualitest Pharmaceuticals2010-08-11Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralTorrent Pharmaceuticals Limited2011-06-03Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralREMEDYREPACK INC.2013-05-302016-10-13Us
Isosorbide MononitrateTablet, extended release60 mg/1OralPd Rx Pharmaceuticals, Inc.1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralCardinal Health1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralAmerican Health Packaging2013-02-15Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralREMEDYREPACK INC.2007-06-132016-11-30Us
Isosorbide MononitrateTablet, extended release30 mg/1OralREMEDYREPACK INC.2016-11-21Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-06-03Not applicableUs
Isosorbide MononitrateTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralRebel Distributors Corp1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralPhysicians Total Care, Inc.2000-11-27Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1Oralbryant ranch prepack1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralUnit Dose Services1998-10-30Not applicableUs
Isosorbide MononitrateTablet10 mg/1OralREMEDYREPACK INC.2016-09-12Not applicableUs
Isosorbide MononitrateTablet30 mg/1OralZydus Pharmaceuticals (USA) Inc.2013-12-19Not applicableUs
Isosorbide MononitrateTablet20 mg/1OralActavis Pharma, Inc.1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release120 mg/1OralMajor Pharmaceuticals2015-01-05Not applicableUs
Isosorbide MononitrateTablet, extended release120 mg/1OralAv Pak2014-04-28Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralSt Marys Medical Park Pharmacy2013-05-15Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralMc Kesson Contract Packaging2013-03-28Not applicableUs
Isosorbide MononitrateTablet, extended release120 mg/1OralTorrent Pharmaceuticals Limited2011-06-03Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralKremers Urban Pharmaceuticals Inc.1998-10-30Not applicableUs
Isosorbide MononitrateTablet60 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-12-19Not applicableUs
Isosorbide MononitrateTablet, extended release120 mg/1OralQualitest Pharmaceuticals2010-08-11Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-06-03Not applicableUs
Isosorbide MononitrateTablet, extended release120 mg/1OralAphena Pharma Solutions Tennessee, Llc1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralCardinal Health2011-06-03Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralREMEDYREPACK INC.2013-03-25Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralProficient Rx LP2010-08-11Not applicableUs
Isosorbide MononitrateTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralHeritage Pharmaceuticals Inc.2010-06-07Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralCardinal Health2010-09-07Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralAphena Pharma Solutions Tennessee, Llc1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralUnit Dose Services2010-06-07Not applicableUs
Isosorbide MononitrateTablet60 mg/1OralZydus Pharmaceuticals (USA) Inc.2013-12-19Not applicableUs
Isosorbide MononitrateTablet10 mg/1OralActavis Pharma, Inc.1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralREMEDYREPACK INC.2015-06-15Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralMc Kesson Contract Packaging2013-02-28Not applicableUs
Isosorbide MononitrateTablet, film coated, extended release60 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-03-30Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralRebel Distributors Corp1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release120 mg/1OralKremers Urban Pharmaceuticals Inc.1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralA S Medication Solutions2011-06-03Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralMajor Pharmaceuticals2015-01-05Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralAv Pak2012-12-13Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralLake Erie Medical DBA Quality Care Products LLC1998-10-30Not applicableUs
Isosorbide MononitrateTablet, film coated, extended release30 mg/1OralMc Kesson Contract Packaging2011-09-13Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralCardinal Health2013-02-15Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralA S Medication Solutions2010-08-11Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-08-11Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralLake Erie Medical DBA Quality Care Products LLC1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralCardinal Health2010-09-07Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralAphena Pharma Solutions Tennessee, Llc1998-10-30Not applicableUs
Isosorbide MononitrateTablet120 mg/1OralZydus Pharmaceuticals (USA) Inc.2013-12-19Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralQualitest Pharmaceuticals2010-08-11Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralTorrent Pharmaceuticals Limited2011-06-03Not applicableUs
Isosorbide MononitrateTablet20 mg/1OralREMEDYREPACK INC.2013-03-182016-10-13Us
Isosorbide MononitrateTablet, extended release60 mg/1OralREMEDYREPACK INC.2015-11-12Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralMc Kesson Contract Packaging2013-06-13Not applicableUs
Isosorbide MononitrateTablet, film coated, extended release30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-03-30Not applicableUs
Isosorbide MononitrateTablet, extended release120 mg/1OralRebel Distributors Corp1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralPhysicians Total Care, Inc.2000-11-27Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1Oralbryant ranch prepack1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralCarilion Materials Management1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralA S Medication Solutions2011-06-03Not applicableUs
Isosorbide MononitrateTablet, coated20 mg/1OralWest ward Pharmaceutical Corp2000-10-05Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralMajor Pharmaceuticals2015-01-05Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralAv Pak2012-12-13Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralSt Marys Medical Park Pharmacy2013-05-15Not applicableUs
Isosorbide MononitrateTablet, film coated, extended release60 mg/1OralMc Kesson Contract Packaging2011-11-28Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralCardinal Health2013-02-15Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralA S Medication Solutions1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release60 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-08-11Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-06-13Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralCardinal Health1998-10-30Not applicableUs
Isosorbide MononitrateTablet, extended release30 mg/1OralAmerican Health Packaging2013-02-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ChemydurNot Available
CoranginNot Available
DilatrateNot Available
DurideNot Available
ElantanNot Available
EtimonisNot Available
ImodurNot Available
ImtrateNot Available
IsmexinNot Available
IsmoNot Available
IsmoxNot Available
IsomonNot Available
IsomonitNot Available
IsonormNot Available
MedocorNot Available
MonicorNot Available
MonitNot Available
Mono CoraxNot Available
Mono MackNot Available
MonocedocardNot Available
MonoclairNot Available
MonocordNot Available
Monodur DurulesNot Available
MonolongNot Available
MonomaxNot Available
MononitNot Available
MonoprontNot Available
MonosorbNot Available
MonosordilNot Available
MonotrateNot Available
NitraminNot Available
OlicardNot Available
OlicardinNot Available
OrasorbilNot Available
PertilNot Available
PlodinNot Available
PromocardNot Available
SigacoraNot Available
SolotrateNot Available
SorbimonNot Available
TurimonitNot Available
UniketNot Available
VasdilatNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIILX1OH63030
CAS number16051-77-7
WeightAverage: 191.1388
Monoisotopic: 191.042987025
Chemical FormulaC6H9NO6
InChI KeyYWXYYJSYQOXTPL-SLPGGIOYSA-N
InChI
InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1
IUPAC Name
(3R,3aS,6S,6aR)-6-hydroxy-hexahydrofuro[3,2-b]furan-3-yl nitrate
SMILES
[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
Pharmacology
IndicationFor the prevention of angina pectoris due to coronary artery disease and the treatment of acute and chronic angina pectoris, hypertension, and myocardial infarction.
Structured Indications
PharmacodynamicsIsosorbide-5-mononitrate, the long-acting metabolite of isosorbide dinitrate, is used as a vasodilatory agent in the management of angina pectoris. By dilating the vessels, it lowers the blood pressure and reduces the left ventricular preload and afterload, therefore, leads to a reduction of myocardial oxygen requirement.
Mechanism of actionSimilar to other nitrites and organic nitrates, Isosorbide Mononitrate is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase (Atrial natriuretic peptide receptor A). This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Guanylate cyclase soluble subunit alpha-2Proteinyes
inducer
HumanP33402 details
Related Articles
Absorption100%
Volume of distribution
  • 0.6 to 0.7 L/kg
Protein binding5%
Metabolism

Hepatic

Route of eliminationIsosorbide mononitrate is primarily metabolized by the liver, but unlike oral isosorbide dinitrate, it is not subject to first-pass metabolism. Isosorbide mononitrate is cleared by denitration to isosorbide and glucuronidation as the mononitrate, with 96% of the administered dose excreted in the urine within 5 days and only about 1% eliminated in the feces. At least six different compounds have been detected in urine, with about 2% of the dose excreted as the unchanged drug and at least five metabolites.
Half life5 hours
Clearance
  • 120–122 mL/min [Single dose of 60 mg PO]
  • 151–187 mL/min [Single dose of extended-release tablet 60 mg PO]
  • 132-151 mL/min [Multiple doses of extended release tablet 60 mg PO]
  • 119-140 mL/min [Multiple doses of extended release tablet 120 mg PO]
ToxicitySymptoms of overdose include vasodilatation, venous pooling, reduced cardiac output, and hypotension. There are no data suggesting what dose of isosorbide mononitrate is likely to be life-threatening in humans. In rats and mice, there is significant lethality at doses of 2000 mg/kg and 3000 mg/kg, respectively.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Mononitrate.Approved
AliskirenThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Aliskiren.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Isosorbide Mononitrate.Approved
AmiodaroneThe metabolism of Isosorbide Mononitrate can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isosorbide Mononitrate.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Isosorbide Mononitrate.Approved
AprepitantThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Isosorbide Mononitrate.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Arsenic trioxide.Approved, Investigational
AtazanavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Isosorbide Mononitrate.Approved
AtomoxetineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Atomoxetine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Isosorbide Mononitrate.Experimental
BarbitalBarbital may increase the hypotensive activities of Isosorbide Mononitrate.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Isosorbide Mononitrate.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Isosorbide Mononitrate.Approved
BepridilThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isosorbide Mononitrate.Approved
BexaroteneThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isosorbide Mononitrate.Approved
BoceprevirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Isosorbide Mononitrate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isosorbide Mononitrate.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Bromocriptine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Isosorbide Mononitrate.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Bupivacaine.Approved, Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Isosorbide Mononitrate.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Captopril.Approved
CarbamazepineThe metabolism of Isosorbide Mononitrate can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Isosorbide Mononitrate.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Carvedilol.Approved, Investigational
CeritinibThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Ceritinib.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Mononitrate.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Isosorbide Mononitrate.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Cilnidipine.Approved
ClarithromycinThe metabolism of Isosorbide Mononitrate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide Mononitrate.Approved
ClotrimazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Clozapine.Approved
CobicistatThe metabolism of Isosorbide Mononitrate can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Isosorbide Mononitrate can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Isosorbide Mononitrate.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Isosorbide Mononitrate.Approved, Investigational
DarunavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Desflurane.Approved
DexamethasoneThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isosorbide Mononitrate.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Diclofenamide.Approved
DihydroergotamineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Isosorbide Mononitrate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Isosorbide Mononitrate.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Mononitrate.Approved
DoxycyclineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Isosorbide Mononitrate can be decreased when combined with Dronedarone.Approved
DuloxetineIsosorbide Mononitrate may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfavirenzThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Isosorbide Mononitrate.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Enalaprilat.Approved
EnzalutamideThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Isosorbide Mononitrate.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isosorbide Mononitrate.Approved
ErythromycinThe metabolism of Isosorbide Mononitrate can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Isosorbide Mononitrate.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isosorbide Mononitrate.Approved
EthanolEthanol may increase the vasodilatory activities of Isosorbide Mononitrate.Approved
EtravirineThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Etravirine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Fimasartan.Approved
FluconazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Fluconazole.Approved
FluvoxamineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Mononitrate.Approved
FosphenytoinThe metabolism of Isosorbide Mononitrate can be increased when combined with Fosphenytoin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Isosorbide Mononitrate.Approved, Vet Approved
Fusidic AcidThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Fusidic Acid.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Isosorbide Mononitrate.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
HydralazineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Isosorbide Mononitrate.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Hydroflumethiazide.Approved
IdelalisibThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Idelalisib.Approved
IloprostThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Isosorbide Mononitrate can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide Mononitrate.Approved
IndinavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Isosorbide Mononitrate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Isosorbide Mononitrate.Approved
ItraconazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Mononitrate.Approved
LacidipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Lacidipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Levobupivacaine.Approved
LevodopaIsosorbide Mononitrate may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Mononitrate.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Lopinavir.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Mononitrate.Approved
LovastatinThe metabolism of Isosorbide Mononitrate can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Isosorbide Mononitrate can be increased when combined with Lumacaftor.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Isosorbide Mononitrate.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Mononitrate.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Isosorbide Mononitrate.Approved
MethohexitalMethohexital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Mononitrate.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Isosorbide Mononitrate.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
MetipranololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Mononitrate.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isosorbide Mononitrate.Approved, Investigational
MifepristoneThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Mifepristone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Isosorbide Mononitrate.Approved
MitotaneThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Isosorbide Mononitrate.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Isosorbide Mononitrate.Approved
MorphineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nadolol.Approved
NafcillinThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Nafcillin.Approved
NebivololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Isosorbide Mononitrate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Isosorbide Mononitrate can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isosorbide Mononitrate.Approved
NicorandilNicorandil may increase the hypotensive activities of Isosorbide Mononitrate.Approved
NifedipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nifedipine.Approved
NilotinibThe metabolism of Isosorbide Mononitrate can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Isosorbide Mononitrate.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Mononitrate.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Isosorbide Mononitrate.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Isosorbide Mononitrate.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Isosorbide Mononitrate.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Obinutuzumab.Approved
OlaparibThe metabolism of Isosorbide Mononitrate can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isosorbide Mononitrate.Approved, Investigational
OsimertinibThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Osimertinib.Approved
OxprenololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Palbociclib.Approved
PapaverineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Papaverine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Isosorbide Mononitrate can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Isosorbide Mononitrate.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Isosorbide Mononitrate can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Phentolamine.Approved
PhenytoinThe metabolism of Isosorbide Mononitrate can be increased when combined with Phenytoin.Approved, Vet Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Isosorbide Mononitrate.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Pipamperone.Approved
PosaconazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Isosorbide Mononitrate.Approved
PrilocaineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Prilocaine.Approved
PrimidoneThe metabolism of Isosorbide Mononitrate can be increased when combined with Primidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Isosorbide Mononitrate.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Mononitrate.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Isosorbide Mononitrate.Approved
RanolazineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Isosorbide Mononitrate.Approved
RifabutinThe metabolism of Isosorbide Mononitrate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Isosorbide Mononitrate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Isosorbide Mononitrate can be increased when combined with Rifapentine.Approved
RiociguatIsosorbide Mononitrate may increase the hypotensive activities of Riociguat.Approved
RisperidoneIsosorbide Mononitrate may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ritonavir.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Ropivacaine.Approved
RosiglitazoneThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Sacubitril.Approved
SaquinavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Selegiline.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the vasodilatory activities of Isosorbide Mononitrate.Approved, Investigational
SiltuximabThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide Mononitrate.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Isosorbide Mononitrate.Approved
St. John's WortThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TadalafilTadalafil may increase the vasodilatory activities of Isosorbide Mononitrate.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Tamsulosin.Approved, Investigational
TelaprevirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Isosorbide Mononitrate can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isosorbide Mononitrate.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Terazosin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Isosorbide Mononitrate.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Isosorbide Mononitrate.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Thioridazine.Approved
TiclopidineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Isosorbide Mononitrate.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Mononitrate.Approved
TocilizumabThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Tolcapone.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Mononitrate.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isosorbide Mononitrate.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Isosorbide Mononitrate.Approved
UdenafilUdenafil may increase the vasodilatory activities of Isosorbide Mononitrate.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Mononitrate.Approved, Investigational
VardenafilVardenafil may increase the vasodilatory activities of Isosorbide Mononitrate.Approved
VenlafaxineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Mononitrate.Approved
VoriconazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Take without regard to meals.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC01DA14
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (217 KB)
MSDSDownload (66.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.9355
Caco-2 permeable-0.579
P-glycoprotein substrateNon-substrate0.7621
P-glycoprotein inhibitor INon-inhibitor0.7159
P-glycoprotein inhibitor IINon-inhibitor0.9116
Renal organic cation transporterNon-inhibitor0.8563
CYP450 2C9 substrateNon-substrate0.8674
CYP450 2D6 substrateNon-substrate0.8613
CYP450 3A4 substrateSubstrate0.5357
CYP450 1A2 substrateNon-inhibitor0.8532
CYP450 2C9 inhibitorNon-inhibitor0.8769
CYP450 2D6 inhibitorNon-inhibitor0.9106
CYP450 2C19 inhibitorNon-inhibitor0.8469
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9596
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7696
BiodegradationReady biodegradable0.8359
Rat acute toxicity2.0753 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5741
hERG inhibition (predictor II)Non-inhibitor0.9304
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Schering plough corp
  • Actavis elizabeth llc
  • Brightstone pharma inc
  • Dexcel ltd
  • Elan pharmaceutical research corp
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kremers urban co
  • Kv pharmaceutical co
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
  • Promius pharma llc
  • Teva pharmaceuticals usa inc
  • Schwarz gmbh
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral120 mg/1
Tablet, extended releaseOral30 mg/1
Tablet, extended releaseOral60 mg/1
TabletOral10 mg/1
TabletOral120 mg/1
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral60 mg/1
Tablet, coatedOral20 mg/1
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral60 mg/1
Prices
Unit descriptionCostUnit
Imdur er 120 mg tablet4.19USD tablet
Imdur 120 mg 24 Hour tablet3.15USD tablet
Imdur 60 mg 24 Hour tablet3.11USD tablet
Imdur er 60 mg tablet2.99USD tablet
Imdur 30 mg 24 Hour tablet2.87USD tablet
Imdur er 30 mg tablet2.85USD tablet
Monoket 20 mg tablet2.65USD tablet
Ismo 20 mg tablet2.1USD tablet
Monoket 10 mg tablet1.75USD tablet
Isosorbide Mononitrate CR 60 mg 24 Hour tablet1.48USD tablet
Isosorbide Mononitrate CR 30 mg 24 Hour tablet1.16USD tablet
Isosorbide Mononitrate 20 mg tablet0.78USD tablet
Isosorbide Mononitrate 10 mg tablet0.74USD tablet
Imdur 60 mg Extended-Release Tablet0.74USD tablet
Isosorbide mn 20 mg tablet0.72USD tablet
Isosorbide mn 10 mg tablet0.71USD tablet
Apo-Ismn 60 mg Extended-Release Tablet0.42USD tablet
Pms-Ismn 60 mg Extended-Release Tablet0.42USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point88-91 °CNot Available
water solubility1.07E+005 mg/LNot Available
logP-0.15SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility57.0 mg/mLALOGPS
logP-0.74ALOGPS
logP-0.48ChemAxon
logS-0.53ALOGPS
pKa (Strongest Acidic)13.34ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area93.74 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity38.08 m3·mol-1ChemAxon
Polarizability15.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isosorbides. These are organic polycyclic compounds containing an isosorbide(1,4-Dianhydrosorbitol) moiety, which consists of two -oxolan-3-ol rings.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassFurofurans
Sub ClassIsosorbides
Direct ParentIsosorbides
Alternative Parents
Substituents
  • Isosorbide
  • Alkyl nitrate
  • Oxolane
  • Organic nitrate
  • Nitrate ester
  • Organic nitro compound
  • Secondary alcohol
  • Organic nitric acid or derivatives
  • Oxacycle
  • Organic 1,3-dipolar compound
  • Allyl-type 1,3-dipolar organic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Alcohol
  • Organic zwitterion
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Heme binding
Specific Function:
Has guanylyl cyclase on binding to the beta-1 subunit.Isoform 2 acts as a negative regulator of guanylyl cyclase activity as it forms non-functional heterodimers with the beta subunits.
Gene Name:
GUCY1A2
Uniprot ID:
P33402
Molecular Weight:
81749.185 Da
References
  1. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109-42. [PubMed:1852778 ]
  2. Mancuso C, Navarra P, Preziosi P: Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J Neurochem. 2010 May;113(3):563-75. doi: 10.1111/j.1471-4159.2010.06606.x. Epub 2010 Jan 20. [PubMed:20089135 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 04, 2016 18:03